By Ilan Zipkin
Staff Writer

A venture capital fund with roots in big pharma, International BM Biomedicine Holdings Inc. is putting together a portfolio of biotechnology companies that resemble a research partnership portfolio for pharmaceutical R&D. That perspective should come as no surprise, as Biomedicine Partners, the fund's management team, includes Jurgen Drews, former president of global R&D at Roche; Fritz Buhler, formerly responsible for worldwide clinical R&D at Roche; and Stefan Ryser, former head of the research staff of global pharma